{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.6","upperLimit":"11.3","value":"5.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nCapivasertib: Given PO","id":"OG000","title":"Treatment (Capivasertib)"}],"paramType":"MEDIAN","populationDescription":"Patients who were eligible and received protocol treatment","reportingStatus":"POSTED","timeFrame":"Assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}